Company intelligence / Profile preview
Barricade Therapeutics
Fort Worth, Texas, United Statesbarricadetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
BT-1501 has completed GLP Toxicology studies and is in IND preparation for colorectal cancer. The company expects to begin clinical trials in 2025. They have also demonstrated biological effects of their TASIN compounds in an animal model of MS.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
The University of Texas Southwestern Medical Center (technology licensing)
Beyond the preview
Go deeper on Barricade Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Barricade Therapeutics.